Waud Capital Partners, a private equity firm focused on healthcare and software technology investments, has appointed Prithvi Raj as its Chief AI and Data Officer. In this new position, Mr. Raj will lead the firm’s efforts to develop and implement artificial intelligence and advanced data strategies across Waud Capital and its portfolio companies. He will work closely with investment teams, portfolio operations, and management to identify growth opportunities, enhance decision-making, and drive measurable value creation across the portfolio.

Health Technology Insights: Study Confirms AISAP AI Can Detect Heart Disease from Ultrasound

Reeve Waud, Managing Partner at Waud Capital Partners, said that Mr. Raj’s appointment highlights the firm’s belief that AI and data are essential for building market-leading companies. He added that Prithvi’s expertise in developing enterprise-level AI and analytics and translating them into tangible business results will strengthen partnerships with management teams and accelerate value creation across their investments.

Health Technology Insights: FuturHealth Adds Wegovy Pill to Its Wellness Solutions

Mr. Raj brings significant experience in AI, data science, and product analytics. He previously served as General Manager and Head of AI and Data at Newmark, overseeing enterprise-wide AI strategy, data infrastructure, and machine learning initiatives. Earlier in his career, he held senior roles at Microsoft, Zynga, and SquareFoot, focusing on using data to drive strategic growth and business performance.

Expressing enthusiasm for his new role, Mr. Raj said he looks forward to joining Waud Capital Partners at a time when AI is transforming how businesses operate and innovate. He emphasized that the firm’s focus on healthcare and technology, combined with its collaborative approach with management teams, provides a unique opportunity to build AI and data capabilities that improve decision-making and support sustainable growth across the portfolio.

Health Technology Insights: Genentech Reports Positive Phase II Results for Obesity Drug CT-388

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com